OA11728A - Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. - Google Patents

Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. Download PDF

Info

Publication number
OA11728A
OA11728A OA1200100150A OA1200100150A OA11728A OA 11728 A OA11728 A OA 11728A OA 1200100150 A OA1200100150 A OA 1200100150A OA 1200100150 A OA1200100150 A OA 1200100150A OA 11728 A OA11728 A OA 11728A
Authority
OA
OAPI
Prior art keywords
polymer
set forth
molécule
pharmaceutically active
compound
Prior art date
Application number
OA1200100150A
Other languages
English (en)
Inventor
Stephen J Comiskey
Stephen J Hanley
Rachel S Kohn
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of OA11728A publication Critical patent/OA11728A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
OA1200100150A 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. OA11728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
OA11728A true OA11728A (en) 2005-02-01

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100150A OA11728A (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.

Country Status (35)

Country Link
EP (1) EP1140026B1 (sr)
JP (1) JP4759141B2 (sr)
KR (1) KR100707710B1 (sr)
CN (1) CN1195497C (sr)
AP (1) AP1769A (sr)
AR (1) AR021652A1 (sr)
AT (1) ATE303795T1 (sr)
AU (1) AU770673B2 (sr)
BG (1) BG65500B1 (sr)
BR (1) BR9916276A (sr)
CA (1) CA2355077C (sr)
CR (1) CR6424A (sr)
CZ (1) CZ301947B6 (sr)
DE (1) DE69927177T2 (sr)
DK (1) DK1140026T3 (sr)
EA (1) EA004502B1 (sr)
EE (1) EE200100314A (sr)
ES (1) ES2245128T3 (sr)
HK (1) HK1041645B (sr)
HR (1) HRP20010446A2 (sr)
HU (1) HU226586B1 (sr)
ID (1) ID28909A (sr)
IL (2) IL143761A0 (sr)
ME (2) MEP19408A (sr)
NO (1) NO20012981L (sr)
NZ (1) NZ511962A (sr)
OA (1) OA11728A (sr)
PL (1) PL196822B1 (sr)
RS (1) RS50123B (sr)
SK (1) SK285812B6 (sr)
TR (1) TR200101759T2 (sr)
TW (1) TWI221418B (sr)
UA (1) UA73101C2 (sr)
WO (1) WO2000035423A1 (sr)
ZA (1) ZA200104899B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
AU2002256694A1 (en) * 2001-03-20 2002-10-03 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
SK14182003A3 (sk) 2001-05-23 2004-05-04 Hexal Ag Homogenizát pre implantáty a mikročastice
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
AU2005287743B2 (en) * 2004-09-21 2011-09-29 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
MX2022007977A (es) * 2019-12-31 2022-07-05 Wanka Tanka Ltd Formulacion plastica de liberacion prolongada.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (sr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
ATE226091T1 (de) * 1990-05-16 2002-11-15 Southern Res Inst Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
EP1140026B1 (en) 2005-09-07
HK1041645B (zh) 2005-07-29
JP2002532408A (ja) 2002-10-02
SK8282001A3 (en) 2001-11-06
IL143761A0 (en) 2002-04-21
YU41401A (sh) 2003-12-31
EA200100551A1 (ru) 2001-10-22
DE69927177T2 (de) 2006-06-08
KR100707710B1 (ko) 2007-04-18
CN1330536A (zh) 2002-01-09
AP2001002198A0 (en) 2001-09-30
DE69927177D1 (de) 2005-10-13
CA2355077A1 (en) 2000-06-22
EA004502B1 (ru) 2004-04-29
TWI221418B (en) 2004-10-01
HUP0105048A2 (hu) 2002-05-29
EE200100314A (et) 2002-08-15
ID28909A (id) 2001-07-12
CA2355077C (en) 2009-05-26
BR9916276A (pt) 2001-09-04
UA73101C2 (en) 2005-06-15
BG105591A (en) 2002-01-31
WO2000035423A1 (en) 2000-06-22
TR200101759T2 (tr) 2001-12-21
ES2245128T3 (es) 2005-12-16
MEP19408A (en) 2010-06-10
AP1769A (en) 2007-08-22
PL348233A1 (en) 2002-05-20
AU1742500A (en) 2000-07-03
IL143761A (en) 2006-08-01
HUP0105048A3 (en) 2002-09-30
RS50123B (sr) 2009-03-25
NO20012981D0 (no) 2001-06-15
NO20012981L (no) 2001-07-27
SK285812B6 (sk) 2007-08-02
KR20010082359A (ko) 2001-08-29
CR6424A (es) 2004-02-26
ME00066B (me) 2010-06-10
BG65500B1 (bg) 2008-10-31
CZ301947B6 (cs) 2010-08-11
NZ511962A (en) 2003-06-30
CZ20012157A3 (cs) 2001-09-12
EP1140026A1 (en) 2001-10-10
PL196822B1 (pl) 2008-02-29
WO2000035423A9 (en) 2002-08-22
JP4759141B2 (ja) 2011-08-31
DK1140026T3 (da) 2006-01-02
AU770673B2 (en) 2004-02-26
AR021652A1 (es) 2002-07-31
HK1041645A1 (en) 2002-07-19
HRP20010446A2 (en) 2002-06-30
HU226586B1 (en) 2009-04-28
CN1195497C (zh) 2005-04-06
ATE303795T1 (de) 2005-09-15
ZA200104899B (en) 2002-09-16

Similar Documents

Publication Publication Date Title
CA2355077C (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
US6455526B1 (en) Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
EP2968320B1 (en) Organic compounds
HU228177B1 (en) Controlled release formulation containing tramadol
JP2012193186A (ja) 放出制御製剤処方物、単位用量形態、乾燥顆粒、マルチ粒子、調製方法、共重合体の使用、および製剤処方物における耐改ざん性を付与する方法
DE102005047561A1 (de) Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
PT1986650E (pt) Formas de dosagem resistentes à adulteração
KR20160113296A (ko) Cgrp-활성 화합물에 대한 정제 제제
EP3454837B1 (en) Use of amino sugar as plasticizer
CA2273272C (en) Immediate release drug delivery forms
MXPA01005920A (es) Antagonista del receptor de serotonina encapsulada de polimero biodegradable y metodo para preparar el mismo
CN1297448A (zh) 帕罗西汀抗坏血酸盐
Kallakunta A Novel Dimension of Twin-Screw Technology for Controlled Release and Solubility Enhancement: Study on Effect of Formulation and Process Parameters
WO2023126977A1 (en) High dose pharmaceutical composition containing dexamethasone and its salt.
HK1092715A1 (en) Melt-formulated, multi-particulate oral dosage form
HK1092715B (en) Melt-formulated, multi-particulate oral dosage form